Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) can be injected regardless of whether you have eaten — unlike some oral medicines, it is a subcutaneous injection and food in your stomach does not affect how the drug is absorbed into your bloodstream. The NHS tirzepatide medicines page confirms there are no food-timing restrictions for the injection. That said, when you choose to inject relative to a meal can shape how comfortable you feel immediately afterwards, and that practical question is worth answering properly. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Mounjaro Summary of Product Characteristics, published on the electronic Medicines Compendium, states that tirzepatide may be injected at any time of day, with or without food, and that the injection site (abdomen, thigh or upper arm) should be rotated each week. There is no instruction to fast beforehand, and no restriction on eating immediately afterwards. This is a meaningful difference from oral GLP-1 medicines, the Wegovy tablet, for example, requires a strict fasting window because absorption depends on passing through the stomach lining. Tirzepatide bypasses that entirely; it moves directly from the subcutaneous tissue into the bloodstream. The Mounjaro SmPC on the eMC is the authoritative reference for the full list of administration instructions, and it is worth reading alongside the patient information leaflet that comes with your pen.
What the guidance does not address is comfort, and that is where most people's real question lives. Pharmacologically, the stomach's contents are irrelevant. Practically, they are not.
Tirzepatide works partly by slowing gastric emptying, food moves out of the stomach more slowly than it would without the medicine. In SURMOUNT-1, the pivotal phase-3 trial published in the New England Journal of Medicine, gastrointestinal side effects were the most commonly reported events, with nausea affecting a meaningful proportion of participants, particularly in the early weeks of treatment and after each dose step up. When you layer a large meal on top of already-slowed gastric emptying, the stomach can feel stretched and sluggish for longer than usual. That is not dangerous. It is uncomfortable, and it is avoidable.
A common pattern reported by people experiencing stomach discomfort on Mounjaro is injecting in the evening and then eating a normal-sized dinner shortly afterwards, only to feel heavy and unsettled overnight. Shifting the injection to a point in the day when you can follow it with a lighter meal (or waiting until a few hours after a larger one) is a practical adjustment worth discussing with your prescriber. It does not change the medicine's effect; it changes your experience of the first 24 hours after each dose.
Consistency matters more than perfection. Tirzepatide has a long half-life, so missing your usual day by 12 or even 24 hours occasionally has minimal clinical impact, your prescriber and the patient information leaflet can advise on that specifically. What does matter is picking a day you can reliably stick to. A question our prescribers hear regularly is whether Monday is a sensible choice: it works well for some people, less well for those whose Mondays involve long meetings or irregular meals. Friday works well for others who prefer a quieter weekend to settle into a new dose. If you travel frequently or your schedule shifts around bank holidays and half-terms, a mid-week day often proves more predictable.
For a broader picture of how tirzepatide sits within a private weight management route, the tirzepatide overview covers mechanism, eligibility and the SURMOUNT programme results in full. For a direct comparison of taking Mounjaro with food versus on an empty stomach (and whether either approach helps with nausea) the empty stomach guide covers the other side of this question.
Mild nausea and a sense of fullness in the first few days after an injection or a dose increase are expected. They typically settle. What to watch for is pain that is severe, persistent, or that radiates to the back, that pattern warrants urgent medical review, because in January 2026 the MHRA issued a Drug Safety Update highlighting acute pancreatitis as a known, infrequent but serious risk with GLP-1 medicines. It is rare, but worth knowing. If you are experiencing that kind of pain, contact a healthcare professional or call 111 rather than waiting for your next prescription review. The Mounjaro stomach pain guide sets out clearly which symptoms are routine and which need prompt attention.
Persistent or worsening GI symptoms that are affecting your appetite and daily routine are also worth flagging to your prescriber, sometimes a slower titration schedule or a temporary hold on dose progression makes a significant difference to tolerability. If you are dealing with ongoing soreness or nausea, that conversation is always appropriate. You can also find cost and access context on the Eli Lilly Mounjaro price increase page if you are weighing up the financial side of continuing treatment.
If you have not yet started Mounjaro and are considering whether it is right for you, check your eligibility with our prescribers, consultation is free, and a real clinician reads every submission the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.